Trevi Therapeutics, Inc.
NASDAQ:TRVIBiotechnology
+$0.43 today
- Market cap
- $1.93B
- Beta
- 1.05
- P/E (TTM)
- -53.6
- EPS (TTM)
- -$0.31
Volume 2.02M
Average 1.44M
TRVI Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Trevi Therapeutics, Inc.NASDAQ: TRVI
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation growth accelerates
Q3 FY2026 stock-based compensation of $3.37M rose 170.8% year over year, ahead of the +114.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 2.9% from the prior quarter. Over 3 fiscal years it compounded at +30.6% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +170.8% holds above the trailing-twelve-month pace of +114.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 5.19M USD
- Year-over-year change
- +44.5%
- 4-year CAGR
- +19.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.19M | +44.5% |
| FY2024 | 2024-12-31 | 3.59M | +59.7% |
| FY2023 | 2023-12-31 | 2.25M | -3.4% |
| FY2022 | 2022-12-31 | 2.33M | -8.5% |
| FY2021 | 2021-12-31 | 2.54M | — |
Stock-Based Compensation vs competitors
How TRVI compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +114.2% is the 2nd highest of 9, against a peer median of -1.0%.
- Over three fiscal years its annual growth of +30.6% compares with a peer median of +46.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $59.52M USD | -4.5% | — | 5.2% | |
| LTM Jun 2026 | $54.95M USD | +126.3% | +46.9% | 12.2% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $21.78M USD | +70.4% | +213.9% | 108.9% |
| LTM Mar 2026 | $18.1M USD | -14.0% | -22.5% | 16.5% | |
| LTM Mar 2026 | $12.55M USD | +2.5% | +2.8% | 18.0% | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $12.34M USD | +54.4% | +100.6% | 371.6% |
| LTM Sep 2026 | $10.18M USD | +114.2% | +30.6% | — | |
| LTM Mar 2026 | $1.31M USD | -131.3% | — | — | |
VCREVicore Pharma Holding AB | LTM Jun 2026 | SEK 286.79K SEK | -324.0% | — | 21.6% |
| Peer median (excluding TRVI) | — | -1.0% | +46.9% | 18.0% | |
Competitors are the stored peer set for TRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (33.94M) | (29.15M) | (29.07M) | (47.91M) | (42.76M) |
| Depreciation & Amortization | 50K | 43K | 123K | 147K | 144K |
| Deferred Income Tax | (82K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.54M | 2.33M | 2.25M | 3.59M | 5.19M |
| Change in Working Capital | 1.51M | (1.23M) | (3.85M) | 6.83M | (3.49M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 831K | 9K | (1.05M) | 1.61M | (598K) |
| Other Working Capital | 678K | (1.24M) | (2.8M) | 5.22M | (2.89M) |
| Other Non-Cash Items | 974K | (162K) | (1.17M) | (907K) | (1.17M) |
| Operating Cash Flow | (28.95M) | (28.18M) | (31.71M) | (38.26M) | (42.09M) |
| Capital Expenditures | 0 | (159K) | (137K) | (35K) | (12K) |
| Acquisitions (Net) | 0 | (829K) | 0 | 0 | 0 |
| Purchases of Investments | 0 | (126.22M) | (9.93M) | (98.46M) | (170.66M) |
| Sales of Investments | 0 | 19M | 69.5M | 75.6M | 74.93M |
| Other Investing Activities | 0 | 829K | 0 | 1.37M | 1.64M |
| Investing Cash Flow | 0 | (107.37M) | 59.43M | (21.53M) | (94.11M) |
| Debt Repayment | (68K) | (5.83M) | (9.41M) | (126K) | 0 |
| Common Stock Issued | 21.18M | 105.41M | 1.71M | 61.15M | 120.3M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (340K) | 11.73M | (211K) | 464K | 714K |
| Financing Cash Flow | 20.78M | 111.31M | (7.91M) | 61.48M | 121.01M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (8.17M) | (24.24M) | 19.81M | 1.7M | (15.18M) |
| Free Cash Flow | (28.95M) | (28.33M) | (31.85M) | (38.29M) | (42.1M) |
Trevi Therapeutics, Inc.
NASDAQ:TRVI
Intrinsic Alpha fair value
Locked
Current Price
$13.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.